Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyae176 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Tsuyoshi Hirata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22, Honko…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aniline Compounds, Acrylamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including both sensitizing and T790M resistance mutations. Its real-world efficacy against uncommon EGFR mutations remains under-researched.
Methods
The REIWA study, a multicentric, prospective, observational study conducted in Japan from September 2018 to August 2020, enrolled patients with advanced or recurrent EGFR mutation-positive NSCLC receiving osimertinib. Data on clinical outcomes, safety, disease progression, and subsequent treatments were collected for patients with uncommon EGFR mutations.
Results
Of 583 patients receiving osimertinib, 39 (6.7%) had an uncommon EGFR mutation. The present study included 32 of these patients after excluding seven patients with an exon 20 insertion mutation. The overall objective response rate was 53.1% [95% confidence interval (CI): 36.4–69.1], and the disease control rate was 78.1% (95% CI: 61.0–89.3). The median progression-free survival was 9.4 months (95% CI: 5.0–20.0), and the median overall survival (OS) was 21.8 (95% CI: 14.4–NA) months. Notably, patients with an exon21 L861Q mutation had a significantly longer OS than those with an exon18 G719X mutation, the respective values being 37.8 and 9.7 months (hazard ratio: 0.29; 95% CI: 0.10–0.85; P = 0.02). The rate of grade 3 or worse adverse events was 10.3%. Seven out of 32 (21.9%) patients showed progression involving only the central nervous system.
Conclusions
Osimertinib demonstrated efficacy and tolerability in the clinical setting in patients with uncommon EGFR mutation-positive NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
- Department of Respiratory Medicine, NTT Medical Center Tokyo, 5-9-22, Higashigotanda, Shinagawa-ku, Tokyo 141-0022, Japan.
- Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1, Ohmorinishi, Ota-ku, Tokyo 143-8541, Japan.
- Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, 1-6, Kandasurugadai, Chiyoda-ku, Tokyo 101-8309, Japan.
ORCID-Profile: Tsuyoshi Hirata, Kageaki Watanabe
Zitieren
APA
Hirata, T., Watanabe, K., Hosomi, Y., Yoh, K., Usui, K., Kishi, K., Naka, G., Tamano, S., Uemura, K., & Kunitoh, H. (2025). Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae176
Vancouver
Hirata T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, et al. Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae176
BibTeX
@article{Hirata2025,
author = {Hirata, Tsuyoshi and Watanabe, Kageaki and Hosomi, Yukio and Yoh, Kiyotaka and Usui, Kazuhiro and Kishi, Kazuma and Naka, Go and Tamano, Shu and Uemura, Kohei and Kunitoh, Hideo},
title = {Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyae176}
}
EUVIMED